Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2020-09-22
2021-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of COVID-19 Using Breath Analysis - Feasibility Study
NCT04602871
Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19)
NCT04556318
Detection of COVID-19 Subjects Using DiaNose Exhalation Test
NCT04476927
Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients
NCT04472728
Bioaerosol Sampling Device (BSD) Clinical Study
NCT06047067
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 Positive patients
subjects who were found COVID-19 Positive according to swab test.
Breath biopsy sampling using the ReCIVA Breath Sampler
Breath biopsy sampling using the ReCIVA Breath Sampler
Healthy subjects
subjects who were found COVID-19 Negative according to swab test.
Breath biopsy sampling using the ReCIVA Breath Sampler
Breath biopsy sampling using the ReCIVA Breath Sampler
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Breath biopsy sampling using the ReCIVA Breath Sampler
Breath biopsy sampling using the ReCIVA Breath Sampler
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive results for SARS-CoV-2
* Capable of understanding written and/or spoken language
* Able to provide informed consent
Exclusion Criteria
* (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypoventilation, respiratory failure, or claustrophobia when wearing the sampling mask
* Persons under guardianship or deprived of liberty
* Patients with the following diseases: Cancer, Asthma, Chronic Respiratory Disease
* Pregnant women
* Treated with antiviral drugs upon admission or during hospitalization
* Novices and soldiers in initial training
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Scentech Medical Technologies Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Natalie Dror, PhD
Role: STUDY_DIRECTOR
Scentech Medical Technologies Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IDF COVID 19 Isolation Facility
Ashkelon, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cov-2-IDF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.